JB Chemicals & Pharmaceuticals Q4 FY26 results (Jan–Mar 2026) and concall

Healthcare · Concall AI · Call held 12 May 2026

Company page: JB Chemicals & Pharmaceuticals share price, financials & guidance record

J.B. Chemicals & Pharmaceuticals reported a challenging Q4 FY26 with a 5% revenue de-growth to INR 904 crores, attributed to an operational reset and discontinuation of low-margin trade generics. Despite this, adjusted EBITDA remained flat at INR 241 crores, and margins improved significantly. The India branded business showed robust growth, while international formulations and CDMO faced headwinds. The merger with Torrent Pharma is nearing completion, with management anticipating normalization and synergy realization from Q1 FY27 onwards.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q4 FY26: revenue down 7.2%, net profit down 35.3% against the same quarter last year.

₹ Cr · quarterly

Line item	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26
Revenue	952	956	914	901	1,040 +9%	1,023 +7%	991 +8%	836 −7%
Expenses	679	688	668	670	747	724	721	642
EBITDA	273	268	245	231	293 +7%	298 +11%	270 +10%	195 −16%
Margin	29%	28%	27%	26%	28%	29%	27%	23%
Other income	5	9	7	14	14	14	17	-17
Interest	4	2	2	1	1	1	2	1
Depreciation	40	41	41	44	41	43	44	49
Profit before tax	234	234	210	199	265 +13%	268 +15%	241 +15%	128 −36%
Tax rate	26%	26%	25%	25%	25%	25%	26%	25%
Net profit	173	173	156	150	198 +14%	200 +16%	179 +15%	97 −35%
EPS	11.16	11.15	10.06	9.62	12.68	12.80	11.44	6.01

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls